Last reviewed · How we verify

Cognitive Remediation — Competitive Intelligence Brief

Cognitive Remediation (Cognitive Remediation) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Psychiatry/Neurology.

phase 3 Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Cognitive Remediation (Cognitive Remediation) — New York State Psychiatric Institute. Cognitive Remediation is a behavioral intervention that uses structured training and practice to improve cognitive functions such as attention, memory, and executive function in patients with psychiatric or neurological disorders.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cognitive Remediation TARGET Cognitive Remediation New York State Psychiatric Institute phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cognitive Remediation — Competitive Intelligence Brief. https://druglandscape.com/ci/cognitive-remediation. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing